2025 ISPE Annual Meeting

The 2025 ISPE Annual Meeting will be held in Washington DC from August 22 to 26, 2025. More information on the conference can be found here.

A variety of Sentinel-related work will be featured, including presentations, posters, and more. 

Spotlight Poster

• Characterization of Mothers in the Sentinel Distributed Database Mother-Infant Linkage Table

Symposia

• Addressing the Threat of Confounding in Pharmacoepidemiology with Innovative Methods: Lessons from the FDA Sentinel Innovation Center
• Developing Computable Phenotypes for Medical Product Safety Surveillance: Innovative Methods and Data Sources
• The Future of Pharmacovigilance: Accelerating Signal Identification with Electronic Healthcare Data
• Overcoming Challenges in CDM Harmonization from Within-Country Coordination to International Collaboration
• Drug Shortage Surveillance: Exploration of Real-World Data

Oral Presentation

• Prevalence of Major Congenital Malformations Among the Insured Population in the United States Using Seven Algorithms

Posters

• Assessment of Utilization Patterns of New Molecular Entities Approved in 2022 using the Sentinel Distributed Database
• Attention-Deficit/Hyperactivity Disorder Medication Utilization Among U.S. Adults Ages 18-64 Years with Commercial Insurance or Medicare: Implications for Design of Inferential Safety Studies
• Cannabis-Related Healthcare Encounters Among Commercially Insured Adults Aged 18-64 years Contributing Data to the US Food and Drug Administration’s Sentinel, 2017-2022
• Characterization of Confounding Covariate Data Capture in the U.S. Food and Drug Administration’s Sentinel Distributed Database
• Electronic Health Record (EHR) Enhanced Signal Detection Using Tree-Based Scan Statistic Methods
• Prevalence of Key Confounding Covariates in a Commercial Electronic Health Records Platform
• Risk of Diabetic Ketoacidosis Across Stages of Chronic Kidney Disease in Patients with Type 1 Diabetes in the U.S. Food and Drug Administration’s Sentinel System
• Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors, Sodium Glucose Cotransporter 2 Inhibitors, or Sulfonylurea in the U.S. Food and Drug Administration’s Sentinel System
• Self-Reported Use of Non-FDA Approved Cannabinoid Products Among Hospitalized Patients in a Large U.S. Hospital Network
• Single-Dose Doxycycline for Lyme Disease Prophylaxis in Children in a Large United States Healthcare Database, 2016-2020
• Strengthening Inferential Studies in the U.S. FDA Sentinel Initiative: Results from a Methodological Demonstration Project
• Use of Glucagon-Like Peptide-1 Receptor Agonists in the U.S. Food and Drug Administration’s Sentinel System
• Utilization of Hormonal Contraceptives During the Postpartum Period in the FDA Sentinel System
• Utilization of Type 2 Diabetes Mellitus Products in the Sentinel Distributed Database, 2008-2024